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Abstract
 
We show that cytotoxic T lymphocytes (CTLs) infiltrating a kidney tumor recognize a peptide
encoded by an alternative open reading frame (ORF) of the macrophage colony-stimulating fac-
tor (M-CSF) gene. Remarkably, this alternative ORF, which is translated in many tumors con-
currently with the major ORF, is also translated in some tissues that do not produce M-CSF,
such as liver and kidney. Such a dissociation of the translation of two overlapping ORFs from
the same gene is unexpected. The antigenic peptide encoded by the alternative ORF is pre-
 
sented by human histocompatibility leukocyte antigen (HLA)-B
 
*
 
3501 and has a length of 14 res-
idues. Peptide elution indicated that tumor cells naturally present this 14 mer, which is the long-
est peptide known to be recognized by CTLs. Binding studies of peptide analogues suggest that
it binds by its two extremities and bulges out of the HLA groove to compensate for its length.
Key words: renal cell carcinoma • HLA-B35 • translation • peptide binding • natural peptide
 
Introduction
 
Antigens recognized by CD8-positive CTLs consist of pep-
tides of 9 to 11 amino acids, which are presented by MHC
class I molecules. The majority of those peptides originate
from the degradation of intracellular proteins, which occurs
in the cytosol and is exerted mainly by the proteasome (for
a review, see reference 1). In recent years, an increasing
number of peptides have been defined that do not simply
result from the degradation of mature proteins, but rather
result from nonclassical mechanisms acting at the level of
transcription, splicing, translation, or processing (2). The
biological significance of those processes had not been rec-
ognized before, presumably because they occur at a low
level and produce limited amounts of materials that are dif-
ficult to detect. It is the exquisite sensitivity of CTLs that
allowed the detection of the products of those processes
and, by inference, the recognition of their actual signifi-
cance. For the immunologist, the practical conclusion is
that the complete spectrum of peptides presented by a
given cell type cannot be deduced from the predicted se-
quence of the major products of the active genes.
Some of those nonclassical peptides result from post-
translational modifications, such as the conversion of an
asparagine residue to an aspartic acid after N-linked glyco-
sylation/deglycosylation reactions, or the oxidation of a
cysteine residue through the formation of a disulfide bridge
with a free cysteine (3–5). Other peptides are encoded by
alternative transcripts starting on cryptic promoters located
in intronic sequences (6, 7). In one case, the alternative
transcript corresponded to the antisense strand of the gene
and therefore resulted from reverse strand transcription (7).
Other peptides are encoded by retained introns resulting
from incomplete splicing (8–10). Lastly, some peptides
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CTLs
 
were found to result from the translation of alternative
open reading frames (ORFs)
 
1
 
 (11–14). In those cases, the
alternative ORF was translated concurrently with the ma-
jor ORF present of the same mRNA, and the expression
of both protein products appeared to parallel the expression
of the corresponding mRNA.
Here we describe a new antigenic peptide, which is rec-
ognized by CTLs directed against human renal cell carci-
nomas (RCCs), and is encoded by an alternative ORF of
the M-CSF gene. Remarkably, this alternative ORF is also
translated in some tissues that do not express M-CSF at the
protein level.
 
Materials and Methods
 
Cell Lines.
 
RCC line LB1047-RCC was derived from a
metastatic lymph node lesion of patient LB1047 (HLA-A
 
*
 
0201,
-A
 
*
 
2402.101, -B
 
*
 
3501, -B51, -Cw
 
*
 
0401, -Cw
 
*
 
1602). The lym-
phoblastoid cell line LB1047-EBV was established by standard
techniques from the lymphocytes present in the culture superna-
tant of the same metastatic lymph node lesion. RCC line
LE9211-RCC and EBV line LE9211-EBV have been described
(15); RCC line HA7-RCC and lymphoblastoid line HA7-EBV
were established in our laboratory from the primary tumor and
peripheral blood lymphocytes of patient HA7 (provided by Drs.
C.G. Stief [Hannover Medical School, Hannover, Germany] and
J. Atzpodien [European Institute for Tumor Immunology and
Prevention, Bonn, Germany); A110L is a lung carcinoma line,
provided by Drs. M. Takenoyama and K. Yasumoto (University
of occupational and Environmental Health, Kita Kyushu, Japan).
Stable transfectant A110L-B35 was obtained by transfection of
the HLA-B
 
*
 
3501 cDNA cloned into plasmid pEF-BOSpuro-PL3
(16). Lines LB2046-PTEC and LB2043-PTEC were described
previously (7). 293-EBNA cells were obtained from Invitrogen.
CTL clones were derived from tumor-infiltrating lymphocytes
(TILs) present in the primary culture of LB1047-RCC. The TILs
were collected at day 3 after the initiation of tumor culture, ex-
panded for 1 wk with IL-6 (10
 
3
 
 U/ml) and IL-12 (10 ng/ml), and
frozen at 
 
2
 
80
 
8
 
C until establishment of the autologous tumor cell
line. TILs were then used as effectors in an autologous mixed
lymphocyte-tumor cell culture (MLTC) performed as described
previously with minor modifications (17). In brief, 10
 
6
 
 TIL-
derived lymphocytes were mixed with 10
 
5
 
 irradiated LB1047-
RCC tumor cells and cultured in human serum with IL-6 (10
 
3
 
U/ml) and IL-12 (10 ng/ml). After 1 wk, 5 
 
3 
 
10
 
5
 
 lymphocytes
were stimulated again for 1 wk with irradiated tumor cells (10
 
5
 
)
with IL-7 (5 ng/ ml) and IL-2 (10 U/ml), and then 1 wk further
with tumor cells and only IL-2 (25 U/ml). On day 21, lympho-
cytes were cloned by limiting dilution in the presence of tumor
cells and allogeneic feeder cells in Iscove’s medium supplemented
with IL-2 (50 U/ml), and long-term culture of CTL clones was
performed as described (17).
 
CTL Assays.
 
Chromium-release, TNF, and IFN-
 
g
 
 stimula-
tion assays were performed as described previously (7). Where in-
dicated, target cells were treated with 100 U/ml IFN-
 
g
 
 24 h be-
fore the assay. For the peptide assay, labeled EBV-transformed B
cells were incubated 30 min at 37
 
8
 
C with various concentrations
of peptides diluted in X-VIVO 10 medium (Whittaker Bioprod-
 
ucts). Lines LB2046- and LB2043-PTEC were transiently trans-
fected with the HLA-B
 
*
 
3501 cDNA using DMRIE-C (GIBCO
BRL) before being used as stimulators for TNF assay. To test the
fractions of peptides eluted from HLA class I molecules of
LB1047-RCC, each fraction was dissolved in 200 
 
m
 
l X-VIVO
10 medium, and 50 
 
m
 
l were pulsed in duplicate onto A110L-B35
(10,000 cells) target cells for 30 min at 37
 
8
 
C. CTL 403A/9 was
then added (5,000 cells) in a final volume of 110 
 
m
 
l of the same
medium with 25 U/ml IL-2; IFN-
 
g
 
 was measured after 18 h.
 
Construction and Screening of the cDNA Library.
 
The cDNA li-
brary was constructed as described recently (16). In brief, mRNA
was transcribed to cDNA with the Superscript Choice System
(GIBCO BRL) using an oligo-(dT) primer containing a NotI site
at its 5
 
9
 
 end. cDNA were then ligated to HindIII adaptors (Strat-
agene), phosphorylated, digested with NotI, size fractionated, and
inserted into the HindIII and NotI sites of expression vector
pCEP4 (Invitrogen). Recombinant plasmids were electroporated
into 
 
Escherichia coli
 
 Top10F
 
9
 
 and selected with ampicillin (100
 
m
 
g/ml). The library was divided into pools of about 100 cDNA
clones. Plasmid DNA of each bacteria pool was extracted using
the QIAprep 8 plasmid kit (QIAGEN).
 
 
 
Pools of about 100
cDNAs were cotransfected into 293-EBNA cells as described
(16). In brief, 5 
 
3
 
 10
 
4 
 
293-EBNA cells were plated in flatbottom
96-well plates and transfected with 60 ng each of both the HLA-
B
 
*
 
3501 and the HLA-Cw
 
*
 
0401 cDNAs cloned into plasmid
pcDNA3 and with about 100 ng of plasmid DNA from each pool
of the cDNA library of LB1047-RCC, using the Lipofectamin™
Reagent (GIBCO BRL). Transfected cells were tested in a CTL
stimulation assay 24 h later.
 
Cloning of HLA cDNA from LB1047-RCC.
 
The
 
 
 
HLA-
B
 
*
 
3501 cDNA was cloned from the total RNA of line LB1047-
RCC using standard reverse transcription (RT)-PCR with HLA
class I–specific primers according to Ennis et al. (18) with Pfu
DNA polymerase (Stratagene). The PCR products were digested
thereafter with KpnI to eliminate HLA-A sequences, phosphory-
lated, and inserted into the EcoRV site of pcDNA3. A selected
plasmid construct was sequenced and confirmed to contain the
HLA-B
 
*
 
3501 cDNA. It was subcloned into plasmid pEF-
BOSpuroPL3.
 
Construction of Minigenes.
 
Minigenes encoding alt.M-CSF
were constructed by PCR using sense primer MPO29 (5
 
9
 
-
ACTGGGCGGATCCTGCCCTCCCACGACATGGCT-3
 
9
 
;
position 153–171 of M-CSF according to GenBank/EMBL/
DDBJ accession no. NM-000757) and antisense primer MPO30
(5
 
9
 
-ACTGCCCGAATTCGTCACGAGGTCTCCATCTGA-
CTG-3
 
9
 
; position 208–225 of M-CSF) or primer MPO39 (5
 
9
 
-
ACTGCCCGAATT
 
CTA
 
TCCTCGGTGATACTCCTG-3
 
9
 
;
position 292–312 of M-CSF), containing a BamHI (MPO29)
and an EcoRI (MPO30 and 39) site (underlined), respectively,
and a stop codon (MPO39; bold). The PCR products were di-
gested with BamHI and EcoRI, inserted into pcDNA3, and se-
quenced, to verify their identity.
 
DNA Sequence Analysis.
 
DNA sequencing reactions were
performed with the ABI PRISM™ dRhodamine Terminator
Cycle Sequencing Kit; the reaction products were separated on
the ABI PRISM™ 310 Genetic Analyser (PerkinElmer).
 
M-CSF Detection.
 
M-CSF was quantified in the culture super-
natant of 10
 
5
 
 cells plated in 0.5 ml of medium in 48-well microtiter
plates for 24 h, using a commercial ELISA kit (R&D Systems).
 
Immunohistochemistry.
 
Immunochemistry was carried out on
sections of frozen or paraffin-embedded RCCs and normal or-
gans. 7-
 
m
 
m frozen sections were fixed in formalin for 5 min at
room temperature and washed in Tris-buffered saline (TBS), pH
 
1
 
Abbreviations used in this paper: 
 
FL, fluorescein; ORF, open reading frame;
RCC, renal cell carcinoma; TIL, tumor-infiltrating lymphocyte. 
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7.4. For formalin-fixed paraffin-embedded tissues, 5-
 
m
 
m sections
were deparaffinized in xylene, hydrated in a graded alcohol series,
and washed in TBS, pH 7.4. Endogenous peroxidase activity was
blocked by incubating all sections in Peroxidase Blocking Re-
agent (Dako) for 10 min at room temperature. Goat IgG (Sigma-
Aldrich) diluted at 0.5 mg/ml in PBS/BSA 0.5% was used to
block nonspecific Ig binding sites for 30 min. For alt.M-CSF de-
tection, we used a polyclonal rabbit antiserum which was raised
against the HPLC-purified synthetic alt.M-CSF peptide coupled
to KLH (EUROGENTEC). The antiserum was purified by affin-
ity chromatography on the synthetic alt.M-CSF peptide coupled
to CNBr-activated sepharose
 
®
 
4B as described by the manufac-
turer (Amersham Pharmacia Biotech) and used at 2 
 
m
 
g/ml. As
control we used 2 
 
m
 
g/ml rabbit IgG, provided by Dr. J.-P. Vaer-
man (Université Catholique de Louvain, Brussels, Belgium).
Staining for M-CSF was done with 12.5 
 
m
 
g/ml of a mouse IgG2a
mAb against human M-CSF (clone 26730.11; R&D Systems). As
isotype control antibody we used the antimelanoma antibody
KBA62 (Immunotech). Incubation with primary antibody and
control antibody was done for 1 or 4 h for alt.M-CSF or M-CSF,
respectively. Binding sites of primary antibodies were visualized
using the mouse or rabbit EnVision™ 
 
1
 
 System, Peroxidase kit
(Dako) according to the manufacturer’s specifications. Enzymatic
color development was performed using 3
 
9
 
3
 
9
 
9-aminoethyl carba-
zole (AEC) as substrate (Dako). Cells were then slightly counter-
stained with hematoxylin III according to Gill (Merck) and
mounted with Faramount aqueous mounting medium (Dako).
Slides were examined under a ZEISS Axioplan microscope
equipped with a Hamamatsu C5810 color chilled 3 CCD camera,
and images were captured by a Scion CG-7 frame grabber.
 
Extraction of HLA-associated Peptides and HPLC Fractionation.
 
Peptides were acid eluted from affinity-purified HLA class I mol-
ecules as described previously with modifications (19). In brief,
10
 
9
 
 LB1047-RCC cells were lysed in buffer containing 20 mM
Tris, pH 8.0, 150 mM NaCl, 1% NP-40, 1 mM PMSF, 5
 
 
 
m
 
g/ml
aprotinin, 10 
 
m
 
g/ml leupeptide, 10 
 
m
 
g/ml pepstatin A, 5 mM
EDTA, and 0.04% sodium azide. After sample centrifugation at
100,000 
 
g
 
 for 1 h, supernatant was filtered (0.22 
 
m
 
m) and pre-
cleared through a Sepharose column (Amersham Pharmacia Bio-
tech). HLA molecules were then affinity-purified using mAb
W6/32 coupled to CNBr-activated Sepharose. After elution of
HLA class I molecules and associated peptides with 10% acetic
acid, pH 2, dissociated peptides were separated from HLA mole-
cules by centrifugation through Ultrafree-CL 5,000-kD filter
(Millipore) at 3,500 
 
g
 
 for 5 h. Peptide extracts were then fraction-
ated by reverse-phase HPLC (rp-HPLC). Aliquots from 10
 
9
 
LB1047 cells were injected on a narrow bore 2 
 
3
 
 150 mm Delta-
pack C18 column (Waters) and eluted using a 60-min linear gra-
dient of acetonitrile in water (0–60%) containing 0.1% trifluoro-
acetic acid at a flow rate of 200 
 
m
 
l/min. The column effluent was
monitored with a UV detector at 210 nm. Fractions of 200 
 
m
 
l
were collected, dried under vacuum, and stored at 
 
2
 
20
 
8
 
C until
use. Synthetic peptides were injected and eluted on the same C18
column under identical conditions.
 
Peptide Binding Assay.
 
Synthetic peptides were made by stan-
dard Fmoc chemistry using a peptide synthesizer Symphony/
Multiplex™ (Protein Technologies Inc.); all peptides were
 
.
 
80% pure by analytical HPLC. Peptides were tested for binding
to HLA-B
 
*
 
3501 in a competition assay as described recently (20).
In brief, 721.221 cells transfected with HLA-B
 
*
 
3501 were
stripped of HLA-bound peptides by mild acid treatment (pH
3.2), and incubated overnight at 4
 
8
 
C with a fluorescein (FL)-
labeled reference peptide at a fixed concentration (250 nM), to-
 
gether with decreasing concentrations (50
 
 
 
to 0.09 
 
m
 
M) of com-
petitor peptides. After washing, the ability of each peptide to
compete the binding of FL-labeled reference peptide was assayed
by measuring the amount of HLA-bound FL-labeled peptide
with a FACScan™ (Becton Dickinson). The reference peptide
was LPSC
 
(FL)
 
ADVEF, a Cys-derivative analogous to the tyrosi-
nase antigenic peptide presented by HLA-B35, LPSSADVEF
(21). The concentration of each peptide needed to inhibit 50%
binding of the FL-labeled peptide (IC50) was calculated accord-
ing to the respective exponential regression curve.
 
Results
 
CTL Clones Recognizing RCC Line LB1047-RCC.
 
By
stimulating in vitro with autologous tumor cells the T lym-
phocytes infiltrating the kidney tumor of patient LB1047,
we obtained a panel of CD8
 
1
 
 CTL clones that specifically
lysed the autologous tumor cells, but not the autologous
EBV-transformed B lymphocytes nor the NK-sensitive
cells K562. Two allogeneic RCC lines expressing HLA-
B35 were also recognized by CTL 403A/9, indicating that
this CTL clone might recognize a shared antigen presented
by HLA-B35 (Fig. 1).
 
Identification of the Antigen Recognized by CTL 403A/9.
 
To identify the antigen recognized by CTL 403A/9, we
constructed a directional cDNA library with mRNA from
tumor line LB1047-RCC as described recently (16). DNA
from this library was transiently transfected into 293-
EBNA cells together with DNA from the autologous
HLA-B
 
*
 
3501 cDNA plasmid construct. We then screened
the transfected cells for their ability to stimulate CTL
403A/9 by adding CTL to the microcultures and measur-
ing the production of IFN-
 
g
 
. We isolated a cDNA which
was able to stimulate CTL 403A/9 when transfected with
the HLA-B
 
*
 
3501 cDNA (Fig. 2).
This cDNA was 4 kb long, and its sequence corre-
sponded to the full-length transcript of the gene encoding
Figure 1. Lytic activity of CTL clone 403A/9. Targets were: autolo-
gous tumor cells LB1047-RCC, allogeneic HLA-B35–positive renal car-
cinoma cells HA7-RCC and LE9211-RCC, and the corresponding
EBV-transformed B cell lines LB1047-EBV, HA7-EBV, and LE9211-
EBV. NK target K562 was also used as control. All target cells were
treated with 100 U/ml IFN-g 24 h before the test. Chromium release
was measured after 4 h. 
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M-CSF, a cytokine also known as CSF-1, which promotes
growth, differentiation, and activation of monocytes, mac-
rophages, and osteoclasts (22, 23). To identify the region of
the M-CSF transcript that encodes the antigenic peptide,
we transfected truncated variants of the cDNA, and found
that fragments containing only the 59-terminal 335 nucle-
otides were able to confer antigenic expression (data not
shown). We tested a series of synthetic peptides derived
from this region of the M-CSF protein sequence for recog-
nition by CTL 403A/9, but they were all negative. We
then analyzed the 59 nucleotidic sequence in the two other
reading phases and identified an alternative ORF encoding
a putative polypeptide of 25 amino acids (alt.M-CSF; Fig. 3
A). To determine whether the antigenic peptide was de-
rived from this polypeptide, we constructed minigenes en-
coding either the full length or the first 20 amino acids of
alt.M-CSF, and transfected them with the HLA-B*3501
cDNA into 293 cells. We observed that CTL 403A/9 rec-
ognized cells transfected with both constructs, suggesting
that the antigenic peptide derived from the first 20 amino
acids of this alternative translation product of the M-CSF
cDNA (Fig. 3 B).
We then tested several synthetic peptides encoded by the
alt.M-CSF sequence, and found that peptide LPAVVGL-
SPGEQEY was able to sensitize autologous EBV-trans-
formed B cells to lysis by CTL 403A/9 (Fig. 3 C). Al-
though class I–binding peptides are usually only 8 to 11
amino acids long, this 14-amino acid peptide appeared to
be optimal as truncation of either the NH2- or the
COOH-terminal residue resulted in the loss of CTL recog-
nition (Fig. 3 C).
Expression of alt.M-CSF. M-CSF is primarily an in-
flammatory cytokine that is not produced in a constitutive
manner but is induced in areas of inflammatory reactions.
Figure 2. Isolation of a cDNA encoding the antigen recognized by
CTL 403A/9. 293-EBNA cells were transfected transiently with cDNA
314 and with a plasmid construct encoding HLA-B*3501. CTL 403A/9
was added after 24 h and the amount of IFN-g in the supernatant was
measured 24 h later. LB1047-RCC cells were used as positive control.
Figure 3. Identification of the peptide recognized by CTL 403A/9. (A) Partial sequence of the 59 end of the M-CSF cDNA, showing the alternative
ORF (boxed) coding for a 25-amino acid polypeptide (alt.M-CSF), and the initial part of the major ORF which encodes the leader sequence and the first
residues of the mature M-CSF, which starts at position 11. The arrow indicates the boundary between exon 1 and 2 (reference 46). The antigenic peptide
in the alt.M-CSF sequence is shown in bold. (B) CTL recognition of cells transfected with minigenes containing the alternative ORF encoding alt.M-CSF.
293-EBNA cells were transfected with plasmids containing HLA-B*3501 and minigenes encoding either the full-length alt.M-CSF product of 25 amino
acids or a truncated product containing the first 20 amino acids. CTL 403A/9 was added after 24 h and production of IFN-g was measured 24 h later. (C)
Recognition of peptide LPAVVGLSPGEQEY by CTL 403A/9. Chromium-labeled LB1047-EBV B cells were incubated 30 min at 378C with the indi-
cated peptides at various concentrations. CTL 403A/9 was added at an effector/target ratio of 10, and chromium release was measured after 4 h.1193 Probst-Kepper et al.
The only tissues that express M-CSF constitutively are the
pregnant uterus, where M-CSF was found to act as a pla-
cental growth and differentiation factor (22, 24), and the
bone marrow, where low constitutive levels of M-CSF
have been detected and appear to control the differentia-
tion of the monocyte/macrophage lineage (25). Despite
this restricted expression of M-CSF, its mRNA is present
in many tissues, including normal liver, kidney, bladder,
and breast (26–28; and data not shown). This suggests that
M-CSF expression is regulated at a posttranscriptional
level. This control appears to be disrupted in certain can-
cers, such as those of the urogenital tract, which frequently
produce high amounts of M-CSF detectable either by im-
munohistochemistry on tissue sections or by ELISA on se-
rum samples. These tumors include breast, ovarian, uterine,
renal, bladder, and prostate carcinomas (22, 29–31). In
some cases, the tumor cells also express the M-CSF recep-
tor, which is the product of protooncogene c-fms, thereby
allowing an autocrine loop that is associated with a poor
prognosis of the tumor disease (32).
A control mechanism also appears to regulate the transla-
tion of alt.M-CSF, the alternative ORF described here, as
we observed that several cell lines expressed the M-CSF
mRNA but were not recognized by our CTL (data not
shown). This implies that the expression profile of this new
antigen cannot be established by RT-PCR. Therefore, we
raised a rabbit antiserum against a synthetic peptide of 25
amino acids corresponding to the entire alt.M-CSF. This
polyclonal antiserum was purified by affinity chromatogra-
phy, but it was found unable to detect the alt.M-CSF pep-
tide on Western blots, presumably because of the small size
of the peptide. However, the antiserum gave a nice specific
signal by immunohistochemistry, and it was used to stain
sections of different kidney tumors. We found that 6/10
RCCs translated alt.M-CSF, including the autologous tu-
mor specimen LB1047-RCC (Fig. 4 B). To determine
whether alt.M-CSF was also translated in normal kidney,
we tested a series of sections derived from biopsies of nor-
mal kidney donors. We observed a strong staining in most
cells of the proximal tubule epithelium (Fig. 4 E). This
Figure 4. Expression of the alt.M-CSF product in tubular kidney cells and in hepatocytes. Paraffin sections from: the renal tumor of patient LB1047
(A and B); a normal kidney biopsy from a graft donor (D and E); or a normal liver (G and H) were stained with either a rabbit control IgG (A, D, and
G) or a rabbit antiserum raised against the alt.M-CSF polypeptide (B, E, and H). Cryosections from: the renal tumor of patient EB56 (C), a normal
kidney sample from patient LB2043 (F), or a normal liver (I) were stained with a monoclonal antibody against M-CSF. Original magnifications: 3200
(A–C) and 3100 (D–I).1194 A Long Out-of-Frame M-CSF Peptide Recognized by Tumor-infiltrating CTLs
staining appeared specific, as it was abolished by blocking
with an excess of alt.M-CSF peptide but not with an irrel-
evant peptide (data not shown). Interestingly, the tubular
cells that were stained with the alt.M-CSF antiserum were
not stained with an antibody directed against the M-CSF
cytokine (Fig. 4 F). This suggests that the translation of the
major ORF and that of the alternative ORF of M-CSF are
regulated independently.
To test directly the recognition of normal tubular kidney
cells by our CTLs, we established short-term cultures from
two different specimens of normal kidney cortex. These
cultures, which were grown in the presence of epithelial
growth factor, were mainly composed of proximal tubular
cells, as determined by expression of aquaporin-1 (7). Both
lines were recognized by CTL403A/9 (Fig. 5). Although
in vivo they do not produce the M-CSF cytokine (Fig. 4
F), the tubular cells grown in vitro secreted detectable
amounts of M-CSF in their supernatant (Fig. 5). This is
presumably related to the cellular activation that is inherent
to in vitro cell culture in the presence of growth factors.
Because of the constitutive expression of alt.M-CSF in
normal renal tubular cells, we also investigated other nor-
mal tissues by immunohistochemistry. We observed a
strong and homogenous staining of normal hepatocytes
(Fig. 4 H). Normal thyroid, lung, stomach, colon, ovary,
and breast were negative, but a few isolated cells of the
duodenal submucosa were also stained (data not shown).
Although they express alt.M-CSF, hepatocytes do not pro-
duce the M-CSF cytokine (Fig. 4 I). Again, these data indi-
cate that the expression of the products of the two ORFs is
differentially regulated, and that translation of alt.M-CSF
can occur in the absence of translation of M-CSF.
Elution of the Natural Peptide Bound to HLA-B35. Pep-
tides presented by MHC class I molecules usually have a
length between 8 and 11 amino acids. The optimal syn-
thetic peptide recognized by our CTLs is 14 amino acids
long. Because of this unusual length, we wanted to deter-
mine whether the natural ligand presented by HLA-B35 at
the surface of the tumor cells was identical to the synthetic
peptide of 14 amino acids. We therefore eluted the pep-
tides bound to the HLA class I molecules purified from
LB1047-RCC cells, and separated the peptides by HPLC.
Fractions were then pulsed onto HLA-B35–positive target
cells, CTL 403A/9 was added, and IFN-g production was
measured to estimate CTL activation. As shown in Fig. 6
A, only fraction 28, which eluted from the HPLC column
after 28 min, was able to stimulate the CTLs, indicating
that it contained the epitope under its natural form. To de-
termine whether the active material present in fraction 28
Figure 5. Recognition of normal kidney cells by CTL 403A/9. Short-
term cell lines LB2046-PTEC and LB2043-PTEC (10,000 cells/well),
which derive from proximal tubular epithelial cells (PTEC), were incu-
bated with CTL 403A/9 (10,000/well), and the production of TNF in
the supernatant was measured after 24 h. In the absence of CTL,
LB2043-PTEC, and LB2046-PTEC produced 2 and 3 pg/ml TNF, re-
spectively. As indicated, both lines were transiently transfected with
HLA-B*3501, to ensure expression of the presenting molecule. Line
LB2046-PTEC, which was already recognized by CTL 403A/9 in the
absence of transfection, was later confirmed to express HLA-B35 natu-
rally. The amount of M-CSF produced by the same cell lines was meas-
ured by ELISA on culture supernatants and is indicated.
Figure 6. Elution of the natural peptide recognized by CTL 403A/9.
(A) HPLC fractions of peptides eluted with acid from the HLA class I
molecules of LB1047-RCC were tested for their ability to stimulate CTL
403A/9 after pulsing onto HLA-B35–positive target cells A110L-B35.
The results of one representative experiment out of three are shown. (B)
Synthetic peptide LPAVVGLSPGEQEY (150 pmol) was injected on the
same HPLC column and its elution was monitored by UV absorption.
(C) 1 pmol of the synthetic peptide was injected on the same column and
the fractions were tested for CTL recognition as indicated in panel A.1195 Probst-Kepper et al.
was identical to the synthetic 14-mer peptide, we ran the
synthetic peptide on the same HPLC column under identi-
cal conditions. We observed that the retention time of the
peptide, measured by UV absorption, was 28.5 min (Fig. 6
B). Furthermore, when the fractions obtained with the
synthetic 14-mer peptide were pulsed onto target cells,
CTL 403A/9 recognized fraction 28, and to a lower extent
fraction 29, but no other fraction (Fig. 6 C). Synthetic pep-
tides extended by one residue at the NH2 terminus or the
COOH terminus were also run on the column and found
by UV absorption to elute at 29.8 and 27.4 min, respec-
tively. Peptides shorter than the 14-mer eluted before 26.5
min. These results demonstrate that the natural peptide is
identical to the synthetic peptide, and has a length of 14
amino acids.
Binding and Recognition of Peptide Analogues of LPAV-
VGLSPGEQEY. The binding motif for HLA-B*3501
has a proline in position 2 and a tyrosine in position 9. The
alt.M-CSF peptide has a proline in position 2 and a ty-
rosine at the COOH terminus. A priori, these two residues
could therefore serve as anchor residues. However, because
of its unusual length, the peptide needs to adopt a nonclas-
sical conformation to fit into the groove of HLA-B35. For
instance, it could either be anchored by its two extremities
and bulge out of the groove in its middle part, or be an-
chored at one end and somewhere in the middle, with the
other end overhanging the HLA cleft (33, 34). To distin-
guish these possibilities, we tested a series of peptide ana-
logues bearing different substitutions at various positions.
The analogues were tested for their ability to bind to HLA-
B35 in a competition assay with a fluorescent unrelated
HLA-B35–binding peptide (Table I). Removal or alanine
substitution of the COOH-terminal tyrosine completely
abolished binding, indicating that the peptide is anchored
by the COOH-terminal tyrosine. However, substitution of
the proline in position 2 with either alanine, tryptophan,
methionine, or glycine only marginally affected HLA-B35
binding, suggesting that this proline is not an anchor resi-
due. In the binding motif for HLA-B35, the proline is lo-
cated in position 27 with regard to the COOH-terminal
tyrosine. At the corresponding position the alt.M-CSF
peptide has a leucine. However, this leucine does not ap-
pear to play a role in binding, as its substitution with ala-
nine did not affect binding. Another proline located in po-
sition  25 from the COOH terminus is apparently not
involved either. Lastly, when the NH2-terminal leucine
was changed into alanine, binding still occurred efficiently,
whereas removal of this leucine completely abolished bind-
ing. Altogether, these results suggest that the peptide is
bound to HLA-B35 via its two extremities: the side chain
of the COOH-terminal tyrosine and the amino group of
the NH2-terminal residue. We therefore speculate that the
middle part of the peptide bulges out of the groove to
compensate for the unusual length of the peptide. This
would make the middle part of the peptide mostly accessi-
ble to the T cell receptor. In line with this prediction,
when we tested the analogues for CTL recognition, we
observed a complete loss of recognition of the analogues
substituted at positions 7 or 9, although these peptides were
very good binders (Table I). As amino acid changes in posi-
tions 1 and 2 also affected to some extent the strength of
CTL recognition, we suggest that the core epitope inter-
acting with the TCR is located at position 7–9, and the na-
ture of residues 1 and 2 contributes to a proper orientation
of the core epitope.
Discussion
The antigenic peptide described here is encoded by an
alternative ORF of the M-CSF gene. The other examples
of peptides encoded by alternative ORF and recognized by
antitumor CTLs were derived from the TRP1, NY-ESO1,
and intestinal carboxyl esterase genes (11–14). In those
cases, the translation of the alternative ORF appeared to
parallel the translation of the major ORF, and there was a
good correlation between the expression of the transcript
and the translation of both ORFs (35). This is not the case
here. The translation of the major and the alternative ORF
of the M-CSF gene appears to be independently con-
trolled. How this control mechanism works is unclear.
Table I. HLA Binding and CTL Recognition of Peptide Analogues
Peptide sequence
Binding to
HLA-B*3501*
IC50 (mM)
Recognition by
CTL 403A/9‡
(pg/ml IFN-g)
FPSDSWCYF§ 4.1 0
WTEAQRLDCWRGGQi .50 0
LPAVVGLSPGEQEY 3.1 12,248
LPAVVGLSPGEQE .50 0
LPAVVGLSPGEQEA¶ .50 0
LAAVVGLSPGEQEY 2.6 576
LWAVVGLSPGEQEY 4.7 2,461
LMAVVGLSPGEQEY 6.5 596
LGAVVGLSPGEQEY 17.4 21
LPAVVGASPGEQEY 1.3 0
LPAVVGLSAGEQEY 1.1 0
LAAVVGLSAGEQEY 1.7 0
APAVVGLSPGEQEY 2.8 674
PAVVGLSPGEQEY .50 0
*Peptides were tested for their ability to compete the binding of FL refer-
ence peptide LPSC(FL)ADVEF, a Cys-derivative analogous to the tyrosi-
nase antigenic peptide presented by HLA-B35 (references 20 and 21). IC50
(mM) represent the concentration of each peptide needed to inhibit 50%
of binding of the FL-labeled reference peptide to 721.221-B*3501 cells.
‡Peptides (50 ng/ml) were pulsed onto target cells A110L-B*3501
(10,000 cells/well). CTL 403A/9 (5,000 cells) was added after 30 min
and the production of IFN-g was tested after 18 h.
§FPSDSWCYF is a B35-binding peptide of CASP-8 (reference 20).
iWTEAQRLDCWRGGQ is derived from gp100 and was used as
negative control.
¶The substituted residue is indicated by underlining in each analogue.1196 A Long Out-of-Frame M-CSF Peptide Recognized by Tumor-infiltrating CTLs
In the previous examples, where the translation of both
ORFs was coordinated, the alternative ORF was also lo-
cated within the major ORF, and it appeared likely that its
translation resulted from a mechanism of leaky scanning,
also named scanthrough (36, 37). This mechanism, first de-
scribed by Kozak et al., occurs when some ribosomes fail to
initiate translation at the first ATG and continue to scan the
mRNA (38, 39). It is favored when the first ATG is not in
an optimal context for efficient initiation. Such an optimal
context, which consists of a purine in position 23 and/or a
guanine in position 14, is absent from the ATG that opens
the major ORF of M-CSF. However, translation of alt.M-
CSF does not seem to result simply from leaky scanning, as
it occurs in the absence of translation of the major ORF, at
least in liver and kidney. A more complex mechanism ap-
pears to be involved. For instance, the translation of the
major ORF, which is presumably cap dependent, could be
inhibited by factors binding the 59 untranslated region
(59UTR) of the mRNA. Such a mechanism has been pro-
posed for TNF, whose translation is repressed in resting
macrophages and induced under inflammatory conditions
(40, 41). In that scenario, the translation of alt.M-CSF
should be cap independent and could result from mecha-
nisms such as those involving internal ribosome entry sites
(IRES), which would allow to overcome the blockade of
cap-dependent translation. Alternatively, because alt.M-
CSF is entirely encoded by exon 2, its translation in liver
and kidney might still be cap dependent but occur on tran-
scripts lacking the first exon and therefore lacking the puta-
tive translational repressor bound to the 59UTR.
Contrary to many antigens recognized by CTLs on mel-
anoma, all the shared antigens currently defined on kidney
cancers are also expressed to some extent in normal tissues
(42). The peptide described here is also not tumor specific,
and it is therefore unclear whether it will be useful for im-
munotherapy of kidney cancer. The fact that CTLs against
such antigens are present in tumor-infiltrating lymphocytes
and were shown in some cases to be amplified in vivo sug-
gests that they can take part in the antitumor response
without obvious autoimmune toxicity (14). However, the
study of animal models has indicated that effective tumor
regressions mediated by such CTLs require the induction
of very strong responses, which then can induce autoim-
mune damage (43).
A remarkable feature of the alt.M-CSF antigenic peptide
is its exceptional length. As far as we know, it is the longest
peptide known to be presented to CD8 T cells by MHC
class I molecules. Given that its structure is closed at both
ends, the groove of the class I molecules cannot accommo-
date such a long peptide in the extended conformation.
The crystal structure of peptides of either 10 or 11 amino
acids combined with class I molecules has indicated that
such peptides can adopt two distinct conformations to fit in
the class I groove. They can either bulge out of the cleft in
their middle part or hang over the edge of the cleft at one
extremity (33, 34, 44). Our results suggest that our 14-mer
peptide adopts the first conformation, being anchored by its
two extremities and protruding out of the groove in its
middle part to compensate for its length. The fact that the
TCR contact site appears to be located in the central part
of the peptide is in line with this structure, which implies
that the protruding part of the peptide is the most accessible
for TCR recognition. The crystal structure of HLA-
B*3501 associated with other peptides has been solved, and
has led to the suggestion that B*3501 might not be able to
accommodate peptides longer than 10 residues (45). This
was based on the observation that the COOH terminus of
peptides bound to B*3501 is placed closer to the A pocket
than in other HLA class I alleles, so that a nonameric pep-
tide already has a tendency to bulge out to fit in the
groove. It was then speculated that longer peptides should
protrude even more to fit, resulting in weaker binding in-
teractions. Our results do not follow this prediction, as we
observed for the 14-mer peptide a binding affinity similar
to that of nonamer FPSDSWCYF, which is considered as a
high-affinity binding peptide (20). Understanding the mo-
lecular basis for this high affinity will clearly require resolu-
tion of the crystal structure of HLA-B*3501 combined
with the alt.M-CSF peptide to confirm the exact confor-
mation of this 14-amino acids peptide in the B35 groove.
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